Lung cancer is the leading cause of cancer-related deaths worldwide. Despite the development and use of several targeting drugs for lung cancer therapy, the five-year survival rate has remained as low as 15% for the past three decades. Cisplatin-based chemotherapy is considered the first-line therapeutic strategy for lung cancer. However, developments of chemoresistance is a major obstacle for the successful treatment. Therefore, the development of novel therapy against cisplatin-resistance lung cancer is imperative. Photodynamic therapy (PDT), which is a non-invasive combinatorial therapeutic modality using light, photosensitizer (PS) and oxygen, may provide an unprecedented tool to develop more effective treatments. To provide experimental basis for its application in cisplatin-resistance lung cancer, we will discuss the biological effects of MPPa-photodynamic therapy in human cisplatin-resistance lung cancer cells in this article. Human cisplatin-resistance lung cancer cells A549/DDP were co-cultured with MPPa (0, 1, 2, 4, 8, 16 μmol/L) and exposed to light (0, 0.6, 1.2, 2.4, 3.6, 4.8 J/cm2), and cell viability was determined with CCK-8 assay. Flow cytometry was used to detect apoptosis, DCFH-DA staining was employed to observe reactive oxygen species (ROS), and Western blot was used to detect the expressions of B-cell lymphoma-2 (Bcl-2) protein and Bcl-2 associated X protein (Bax). The proliferation of A549/DDP cells was suppressed by PDT. The apop-totic rate in the PDT group was significantly higher than that in the control, MPPa or light group (P < 0.05). The level of ROS was increased. The expression of Bax was increased, and that of Bcl-2 was decreased. MPPa-photodynamic therapy can significantly suppress cell viability, and induce apoptosis in human cisplatin-resistance lung cancer cells.
Objective To observe the influence of cisplan on the expression of B7-H1 in retinoblastoma (RB) cells，and to investigate its mechanism. Methods Human RB cell line HXO-Rb44 cells were treated by 6 different concentrations of cisplan (0.000, 0.375, 0.750, 1.500, 3.000, 6.000 mu;g/ml), and their B7-H1 mRNA expression was determined by the reversetranscription polymerase chain reaction (RT-PCR) and fluorescence quantitative PCR (FQ-PCR); the B7-H1 protein expression was determined by immunofluorescence and flow cytometry. HXO-Rb44 cells were treated by 1.5 mu;g/ml cisplan for 0, 15, 30, 60, 120 min, then the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) was detected by Western blot.Results The expression of B7-H1 mRNA and protein in the 0.375, 0.750, 1.500, 3.000, 6.000 mu;g/ml group were significantly higher than that of the blank control group (F=395.478，112.03; P=0.000）. Western blot showed that cisplan (1.5 mu;g/ml) could activate ERK1/2 by increasing its phosphorylation in HXO-Rb44 cells. After cisplan treatment, the phosphorylation of ERK1/2 increased gradually and reached its peak at 30 min, and then went down gradually.Conclusion Cisplan can promote the expression of B7-H1 and activate ERK1/2 in RB cells.
Objective To investigate the utilization of platinum drugs in 21 hospitals of Chengdu from 2011 to 2014. Methods The utilization information of platinum drugs in 21 hospitals of Chengdu from 2011 to 2014 was extracted, and the dosage form of drugs, consumption sum, frequency of drug use (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) were analyzed statistically. Results From 2011 to 2014, the total consumption sums and DDDs of platinum drugs were increased year by year. The consumption sums of oxaliplatin were the highest, and the consumption sums of carboplatin were increased year by year. Oxaliplatin, nedaplatin, and lobaplatin were ranked first, second and fifth respectively in all the four consecutive years; the total DDDs of patinum drugs from 2011 to 2014 showed a trend of increase, DDDs of cisplatin were always ranked first, followed by oxaliplatin; DDC and sorting of platinum drugs were relatively stable, and B/A values of carboplatin and cisplatin were close to 1.00. Conclusion The utilization of platinum drugs in 21 hospitals of Chengdu is in accordance with the principle of safety, effectiveness, economy and convenience.
目的:研究TRAIL对卵巢癌COC1/DDP细胞生长的影响，以及化疗药物DDP等对TRAIL受体（DR4、DR5）表达的影响，揭示TRAIL与COC1/DDP细胞顺铂耐药性的关系。方法:用MTT法检测不同浓度TRAIL蛋白和TRAIL与DDP联合用药对COC1/DDP细胞生长的影响，用RTPCR方法检测DDP对TRAIL受体（DR4、DR5）表达的影响。结果:①TRAIL蛋白对COC1/DDP细胞生长有抑制作用，且随着TRAIL蛋白浓度升高，细胞抑制率逐渐上升。②DDP（2.5μg/mL）对COC1/DDP细胞生长抑制作用较弱（抑制率为3.31%），DDP在加入TRAIL蛋白后对细胞生长抑制率显著升高（Plt;0.05）。③DDP使COC1/DDP细胞的DR5表达水平显著增强为正常对照组的3.54倍（Plt;0.001）。结论:TRAIL蛋白对COC1/DDP细胞生长有抑制作用，DDP与TRAIL联合使用COC1/DDP细胞生长抑制更明显，TRAIL可逆转COC1/DDP细胞对DDP的耐药性，耐药性的逆转可能与DDP导致TRAIL受体DR5水平增高促进了肿瘤细胞的凋亡有关。
目的 观察三氧化二砷联合顺铂腔内注射治疗恶性胸腔积液的疗效和毒副反应。 方法 2011年9月－2012年9月，将恶性胸腔积液患者60例，随机分为治疗组和对照组，每组各30例。在胸腔积液充分引流后，治疗组胸腔内注射三氧化二砷20 mg联合顺铂60 mg；对照组只给予胸腔灌注顺铂60 mg，胸腔灌注化学疗法药物两组均1次/周，共3次。观察疗效及不良反应。 结果 治疗组和对照组的有效率分别为93.3%和56.7%（P＜0.05）。治疗组和对照组的一般状况改善率分别为70.0%和40.0%（P＜0.05）。两组的不良反应相近。 结论 三氧化二砷联合顺铂腔内注射治疗恶性胸腔积液具有协同增效作用，不良反应小。
ObjectiveTo systematically evaluate the efficacy and safety of nedaplatin versus cisplatin combined with fluorouracil in the treatment of esophageal neoplasms.MethodsPubMed, EMbase, Web of Science, The Cochrane Library, CNKI, WanFang, VIP and CBM databases were searched by computer to investigate the randomized controlled studies about the clinical effects of nedaplatin combined with fluorouracil versus cisplatin combined with fluorouracil in the treatment of esophageal neoplasms. The retrieval time was from the establishment of the database to January 2021. And meta-analysis was performed using RevMan 5.4.ResultsA total of 12 randomized controlled studies involving 744 patients were included. The results of meta-analysis showed that the total effective rate of the nedaplatin group was better than that of the cisplatin group (P<0.05). The incidence of nausea, vomiting, diarrhea and renal impairment in the nedaplatin group was lower than that in the cisplatin group (P<0.05), but the incidence of leukopenia and hemoglobin decline was higher than that in the cisplatin group (P<0.05). There was no statistical difference in the incidence of liver injury, or platelet decline between the two groups (P>0.05).ConclusionNedaplatin combined with fluorouracil has more advantages than cisplatin combined with fluorouracil in the treatment of esophageal cancer, the incidence of nausea, vomiting and diarrhea is lower, and the damage to kidney function is also smaller.
目的:评价国产吉西他滨(泽菲)联合顺铂二线治疗晚期乳腺癌的疗效和不良反应。方法:34例晚期乳腺癌患者采用国产吉西他滨1000mg/m2,静脉滴注30min,第1、8天;顺铂25mg/m2,静脉滴注,第1～3天。21d为一个周期,至少完成两周期后评价疗效。结果:完全缓解2例(588%),部分缓解16例(4706%),总有效率为5294%。中位疾病进展时间为65月,中位生存期为114月;主要不良反应为骨髓抑制和胃肠道反应,所有不良反应在停药后或对症处理后均可恢复正常。结论:国产吉西他滨联合顺铂二线治疗晚期乳腺癌疗效较好,毒副反应可耐受,值得进一步研究。
Non-small cell lung cancer (NSCLC) accounts for more than 80% of lung cancer. Nowadays, gemcitabine and cisplatin in combination have been adopted as the first-line chemotherapy for patients with NSCLC. This study aimed to monitor early response to combined chemotherapy of gemcitabine plus cisplatin in a mouse model of NSCLC by using 18F-fluorodeoxyglucose and 18F-fluorothymidine small animal positron emission tomography (PET). Lewis lung carcinoma-bearing C57BL/6 mice were treated with gemcitabine-cisplatin or saline. Small animal PET with 18F-FDG and 18F-FLT was performed before (baseline) and after treatment (on Day 3), respectively. Imaging results were confirmed by histopathological studies (hematoxylin and eosin staining, Ki67 staining). Compared to the results in the control group, gemcitabine-cisplatin in the treated group significantly inhibited tumor growth (P<0.05). In the treated group, the maximum standardized uptake value (SUVmax) of 18F-FLT decreased significantly from 0.59±0.05 (baseline) to 0.28±0.05 (Day 3) (P<0.05). There was no significant difference between baseline (4.35±0.46) and that on Day 3 (4.02±0.47) on 18F-FDG SUVmax (P>0.05). The proliferation of tumor assessed by Ki67 staining decreased significantly after treatment of one dose of gemicitabine-cisplatin (P<0.05). The staining of HE showed an increase in necrotic and inflam- matory cells after the treatment. This study demonstrated that the uptake of 18F-FLT reduced more rapidly and signi-ficantly than that of 18F-FDG and was less disturbed by the increase of inflammatory cells after chemotherapy.
摘要:目的:探讨鼻咽癌放疗后程同步辅以小剂量顺铂增敏的近期疗效,并与常规治疗和后程加速超分割放射治疗进行比较。方法:选取98例Ⅱ～Ⅳ期鼻咽癌患者,随机分为常规治疗组(简称T1组,32例)、后程加速超分割治疗组(简称T2组,32例)和顺铂加后程加速超分割治疗组(简称T3组,34例),并对治疗效果进行比较。 结果:1组鼻咽部肿瘤消除率为75.0%(24／32),颈部淋巴结消除率为87.5%(28/32);T2组鼻咽部肿瘤消除率为87.5%(28／32),颈部淋巴结消除率为84.4%(27/32);T3组鼻咽部肿瘤消除率为97.1%(33／34),颈部淋巴结消除率为91.2%(31/34)。进行两两比较,均为P＜0.05,有统计学意义,疗效:T3 组＞T2 组＞T1组。治疗副作用有增加(P＞0.05),但无统计学意义。 结论:小剂量顺铂加后程加速超分割治疗鼻咽癌,可以达到较常规治疗更好的近期治疗效果。Abstract: Objective: To study the later therapeutic efficacy of nasopharyngeal carcinoma in late course accelerated fractionation (LCAF) radiotherapy and low dose cisplatin, at same time compare with conventional fractionation and LCAF. Methods: Ninetyeight cases with stage ⅡⅣ of nasopharyngeal carcinoma were randomly assigned to three groups: conventional fractionation (T1), LCAF (T2), LCAF and low dose cisplatin (T3). At the end of treatment, therapeutic efficacy was compared with each other. Results: The survey periods was 3 months. Comlete response rate (CR) for groups T1, T2 and T3 was 75.0% (24／32), 87.5% (28／32) and 97.1% (33／34), respectively; the group treated with LCAF and cisplatin had highest effective later therapeutic efficacy than other groups. Lymph node of neck of group T3 got better control, although its side effects were more serious, but no significant difference was found among three group. Conclusion: Combined treatment of LCAF radiotherapy and low dose cisplatin has better later therapeutic efficacy on tumor control in patients with nasopharyngeal carcinoma